- Home
- MKZR vs NCNA Comparison
MKZR vs NCNA Comparison
Compare MKZR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MKZR | NCNA |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | 12 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 5.5M |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MKZR | NCNA |
|---|---|---|
| Price | $1.47 | $1.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.7K | ★ 60.7K |
| Earning Date | 05-14-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,059,843.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.19 | N/A |
| 52 Week Low | $0.83 | $1.21 |
| 52 Week High | $6.99 | $7.01 |
Technical Indicators
Market Signals| Indicator | MKZR | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 42.66 |
| Support Level | $1.37 | $1.33 |
| Resistance Level | $1.84 | $1.41 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 44.44 | 5.18 |
Price Performance
Historical ComparisonAbout MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate. It is a real estate investment manager who utilizes an approach to real estate securities, often seeing opportunities that others overlook. Based in Orinda, California, MacKenzie Capital Management has specialized in discounted real estate securities and asset management.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.